Skip to main content
SpringerLink
Log in

Therapeutic Applications of Bromocriptine in Endocrine and Neurological Diseases

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Bromocriptine, or 2- bromo- α-ergocryptine, is a semisynthetic ergot alkaloid. The basis of its therapeutic application in endocrine and neurological diseases is its action as a potent dopamine agonist. Its ability to inhibit prolactin secretion has led to its successful use in suppression of puerperal lactation and in the treatment of pathological hyperprolactinaemia causing galactorrhoea, infertility or hypogonadism. It has been shown to be safe in pregnancy. The ability of bromocriptine to reduce the size of large prolactin-secreting pituitary tumours has resulted in the recovery of pituitary function and correction of visual field defects. Bromocriptine is less effective in acromegaly but is useful as adjuvant therapy to radiotherapy and/or surgery which has been the standard mode of treatment. It has been shown to be efficacious either alone or in combination with levodopa in the treatment of Parkinson’s disease. Therapy with low doses appears to be effective and is associated with a significantly reduced incidence of side effects. The successful use of bromocriptine has also been reported for the treatment of non-functioning pituitary tumours, premenstrual syndrome, cyclical mastalgia, luteal phase insufficiency and portal-systemic encephalopathy, although its role in the treatment of these latter disorders remains uncertain until more extensive and adequately controlled trials have been conducted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Andersch B, Hahn L, Wendestam C, Ohman R, Abrahamsson L. Treatment of premenstrual tension syndrome with bromocriptine. Acta Endocrinologica (Copenhagen) 88 (Suppl. 216): 165–174, 1978

    Google Scholar 

  • Andersen AN, Larsen JF. Bromocriptine in the treatment of the premenstrual syndrome. Drugs 17: 383–388, 1979

    PubMed  CAS  Google Scholar 

  • Andersen AN, Larsen JF, Steenstrup OR, Svendstrup B, Neilsen J. Effects of bromocriptine on the premenstrual syndrome: a double-blind clinical trial. British Journal of Obstetrics and Gynaecology 1: 370–374, 1977

    Google Scholar 

  • Auborg PR, Derome PJ, Peillon F, Jedynak CP, Visot A, et al. Endocrine outcome after transphenoidal adenectomy for prolactinoma: prolactin levels and tumor size as predictive factors. Surgical Neurology 14: 141–147, 1980

    Google Scholar 

  • Badano AR, Miechi A. Bromocriptine in the treatment of hyperprolactinemic amenorrhea. Fertility and Sterility 31: 124–129, 1979

    PubMed  CAS  Google Scholar 

  • Barrow DI, Tindall GT, Kovacs K, Thorner MO, Hovarth E, et al. Clinical and pathologic effects of bromocriptine on prolactin-secreting and other pituitary tumors. Journal of Neurosurgery 60: 1–7, 1984

    PubMed  CAS  Google Scholar 

  • Baskins DS, Boggan JE, Wilson CB. Transphenoidal microsurgical removal of growth hormone-secreting pituitary adenomas. Journal of Neurosurgery 56: 634–641, 1982

    Google Scholar 

  • Belforte L, Camanni F, Chiodini PG. Long-term treatment with 2-Br-alpha-ergocryptine in acromegaly. Acta Endocrinologica (Copenhagen) 85: 235–248, 1977

    CAS  Google Scholar 

  • Bell MB, Atkinson AB, Hadden DR, Kennedy L, Leslie H, et al. Bromocriptine reduces growth hormone in acromegaly. Archives of Internal Medicine 146: 1145–1149, 1986

    PubMed  CAS  Google Scholar 

  • Benedek-Jaszmann LJ, Hearn-Sturtevan MD. Premenstrual tension and functional infertility. Lancet 1: 1095–1097, 1976

    PubMed  CAS  Google Scholar 

  • Benker G, Gieshoff B, Freundlieb O, Windeck R, Schulte HM, et al. Parental bromocriptine in the treatment of hormonally active pituitary tumours. Clinical Endocrinology 24: 505–513, 1986

    PubMed  CAS  Google Scholar 

  • Bergh T, Nillius SJ, Enoksson P, Wide L. Bromocriptine-induced regression of a suprasellar extending prolactinoma during pregnancy. Journal of Endocrinological Investigation 7: 133–136, 1984

    PubMed  CAS  Google Scholar 

  • Bergh T, Nillius SJ, Eriksson P, Larsson SE, Wide L. Bromocriptine-induced pregnancies in women with large prolactinomas. Clinical Endocrinology 17: 625–631, 1982

    PubMed  CAS  Google Scholar 

  • Bergh T, Nillius SJ, Wide L. Hyperprolactinaemic amenorrhoea — results of treatment with bromocriptine. Acta Endocrinologica (Copenhagen) 88 (Suppl. 216): 147–164, 1978a

    Google Scholar 

  • Bergh T, Nillius SJ, Wide L. Clinical course and outcome of pregnancies in amenorrhoeic women with hyperprolactinaemia and pituitary tumours. British Medical Journal 1: 875–880, 1978b

    PubMed  CAS  Google Scholar 

  • Besser GM, Wass JAH, Thorner MO. Bromocriptine in the medical management of acromegaly. In Goldstein et al. (Eds) Ergot compounds and brain function: neuroendocrine and neuropsychiatric aspects, pp. 191–198. Advances in Biochemical Psychopharmacology. Raven Press, New York, 1980

    Google Scholar 

  • Blichert-Toft M, Andersen AN, Henriksen OB, Mygind T. Treatment of mastalgia with bromocriptine: a double blind crossover study. British Medical Journal 1: 237, 1979

    PubMed  CAS  Google Scholar 

  • Breidahl HD, Topliss DJ, Pike JW. Failure of bromocriptine to maintain reduction in size of a macroprolactinoma. British Medical Journal 287: 452, 1983

    Google Scholar 

  • Brun del Re R, del Pozo E, de Grandi P, Friesen H, Hanselmann M, et al. Prolactin inhibition and suppression of puerperal lactation by a Br-ergocryptine (CB 154): a comparison with estrogen. Obstetrics and Gynecology 41: 854–890, 1973

    Google Scholar 

  • Burrow GN, Wortzman G, Rewcastle NB, Holgate RC, Kovacs K. Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. New England Journal of Medicine 304: 156–158, 1981

    PubMed  CAS  Google Scholar 

  • Caraceni TA, Celano I, Parati E. Bromocriptine alone or associated with L-dopa plus benzeraside in Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry 40: 1142–1146, 1977

    CAS  Google Scholar 

  • Chiodini P, Luizzi A, Cozzi R, Verde G, Oppizzi G, et al. Size reduction of macroprolactinomas by bromocriptine or lisuride treatment. Journal of Clinical Endocrinology and Metabolism 53: 737–743, 1981

    PubMed  CAS  Google Scholar 

  • Clemmons DR, Van Wyk JJ, Ridgway EC, Kliman BC, Kjellberg RN, et al. Evaluation of acromegaly by radioimmunoassay of somatomedin-C. New England Journal of Medicine 301: 1138–1142, 1979

    PubMed  CAS  Google Scholar 

  • Cole EN, Sellwood RA, England PC, Griffiths K. Serum prolactin concentrations in benign breast disease throughout the menstrual cycle. European Journal of Cancer 13: 597–603, 1977

    PubMed  CAS  Google Scholar 

  • Corenblum B, Taylor PJ. Prediction of response to ergocryptine in the galactorrhea-amenorrhea syndrome. Fertility and Sterility 30: 388–392, 1978

    PubMed  CAS  Google Scholar 

  • Corenblum B, Taylor PJ. Long-term follow-up of hyperprolactinemic women treated with bromocriptine. Fertility and Sterility 40: 596–599, 1983

    PubMed  CAS  Google Scholar 

  • Crosignani PG, Ferrari C, Mattei AM. Visual field defects and reduced visual acuity during pregnancy in two patients with prolactinoma: rapid regression of symptoms under bromocriptine. Case reports. British Journal of Obstetrics and Gynaecology 91: 821–823, 1984

    PubMed  CAS  Google Scholar 

  • Dallabonzana D, Spelta B, Oppizzi G. Re-enlargement of macroprolactinomas during bromocriptine treatment: report of 2 cases. Journal of Endocrinological Investigation 6: 47–50, 1983

    PubMed  CAS  Google Scholar 

  • de Wit W, Coelingh Bennink HJT, Gerards LJ. Prophylactic bromocriptine treatment during pregnancy of women with macroprolactinomas: report of thirteen pregnancies. In Aver et al. (Eds) Prolactinomas, an interdisciplinary approach, pp. 397–403, Walter de Gruyter, Berlin, 1985

    Google Scholar 

  • Diamond SG, Markham CH. Evaluating the evaluations: on how to weigh the scales of Parkinsonian disability. Neurology 33: 1098–1099, 1983

    PubMed  CAS  Google Scholar 

  • Eastman RC, Gorden P, Roth J. Conventional supervoltage irradiation is an effective treatment for acromegaly. Journal of Clinical Endocrinology and Metabolism 48: 931–940, 1979

    PubMed  CAS  Google Scholar 

  • Eskildsen PG, Svendsen PA, Vang L, Nerup J. Long-term treatment of acromegaly with bromocriptine. Acta Endocrinologica (Copenhagen) 87: 687–700, 1978

    CAS  Google Scholar 

  • Eversmann T, Fahlbusch R, Rjosk HK, von Werder K. Persistent suppression of prolactin secretion after long term treatment in patients with prolactinomas. Acta Endocrinologica 92: 413–427, 1979

    PubMed  CAS  Google Scholar 

  • Faria MA, Tindall GT. Transphenoidal microsurgery for prolactin secreting pituitary adenomas. Journal of Neurosurgery 56: 33–43, 1982

    PubMed  Google Scholar 

  • Feek CM, McLelland J, Seth J, Toft AD, Irvine WJ, et al. How effective is external pituitary irradiation for growth hormone-secreting pituitary tumours? Clinical Endocrinology 20: 401–408, 1984

    PubMed  CAS  Google Scholar 

  • Fine SA, Frohman LA. Loss of central nervous system component of dopaminergic inhibition of prolactin secretion inpatients with prolactin secreting pituitary tumours. Journal of Clinical Investigation 61: 973–980, 1978

    PubMed  CAS  Google Scholar 

  • Fluckiger E, Doepfner W, Marko M, Nieder W. Effects of ergot alkaloids on the hypothalamic-pituitary axis. Postgraduate Medicine 52 (Suppl.): 57–61, 1976

    Google Scholar 

  • Franks S, Nabarro JD. Prevalence and presentation of hyperprolactinemia in patients with ‘functionless’ pituitary tumours. Lancet 1: 778–780, 1977

    PubMed  CAS  Google Scholar 

  • Gemzell C, Wang CF. Outcome of pregnancy in women with pituitary adenoma. Fertility and Sterility 31: 363–372, 1979

    PubMed  CAS  Google Scholar 

  • Ghose K, Coppen A. Bromocriptine and premenstrual syndrome: controlled study. British Medical Journal 1: 147–148, 1977

    PubMed  CAS  Google Scholar 

  • Grossman A, Cohen BL, Charlesworth M, Plowman PN, Rees LH, et al. Treatment of prolactinomas with megavoltage radiotherapy. British Medical Journal 288: 1105–1109, 1984

    PubMed  CAS  Google Scholar 

  • Grossman A, Ross R, Charlesworth M, Adams CBT, Wass JAH, et al. The effect of dopamine agonist therapy on large functionless pituitary tumours. Clinical Endocrinology 22: 679–686, 1985

    PubMed  CAS  Google Scholar 

  • Grossman A, Ross R, Wass JAH, Besser GM. Depot-bromocriptine treatment for prolactinomas and acromegaly. Clinical Endocrinology 24: 231–238, 1986

    PubMed  CAS  Google Scholar 

  • Hardy J, Mohr G. Le prolactinome: aspects chirurgicaux. Neurochirurgie 27 (Suppl.): 41–60, 1981

    PubMed  Google Scholar 

  • Ho KY, Evans WS, Thorner MO. Disorders of prolactin and growth hormone secretion. Clinical Endocrinology and Metabolism 14: 1–32, 1985a

    CAS  Google Scholar 

  • Ho KY, Smythe GA, Compton PJ, Lazarus L. Long-term bromocriptine therapy may restore the inhibitory control of prolactin release in some patients with pathological hyperprolactinemia. Australian and New Zealand Journal of Medicine 15: 213–219, 1985b

    PubMed  CAS  Google Scholar 

  • Ho KY, Smythe GA, Lazarus L. Prolactin response to dopamine synthesis inhibition using monoiodotyrosine in subjects on oral contraceptives and patients with pathological hyperprolactinemia. Journal of Clinical Endocrinology and Metabolism 56: 692–696, 1983

    PubMed  CAS  Google Scholar 

  • Iffy L, TenHove W, Frisoli G. Acute myocardial infarction in the puerperium in patients receiving bromocriptine. American Journal of Obstetrics and Gynecology 155: 371–372, 1986

    PubMed  CAS  Google Scholar 

  • Johnston DG, Prescott RWG, Kendall-Taylor R, Hall K, Crombie AL, et al. Hyperprolactinemia: long term effects of bromocriptine. American Journal of Medicine 75: 868–874, 1983

    PubMed  CAS  Google Scholar 

  • Jones GS. The luteal phase defect. Fertility and Sterility 27: 351–356, 1976

    PubMed  CAS  Google Scholar 

  • Kanis JA, Gillingham FJ, Harris P. Clinical and laboratory study of acromegaly: assessment before and one year after treatment. Quarterly Journal of Medicine 43: 409–431, 1974

    PubMed  CAS  Google Scholar 

  • Katz M, Kroll D, Pak I. Puerperal hypertension, stroke and seizures after suppression of lactation with bromocriptine. Obstetrics and Gynecology 66: 822–825, 1985

    PubMed  CAS  Google Scholar 

  • Ketabian JW, Calne DB. Multiple receptors for dopamine. Nature 277: 93–96, 1979

    Google Scholar 

  • Kleinberg DL, Noel GL, Frantz AG. Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. New England Journal of Medicine 296: 589–600, 1977

    PubMed  CAS  Google Scholar 

  • Klibanski A, Greenspan SI. Increase in bone mass after treatment of hyperprolactinemic amenorrhea. New England Journal of Medicine 315: 542–546, 1986

    PubMed  CAS  Google Scholar 

  • Klibanski A, Neer RM, Beitins IZ, Ridgeway EC, Zervas NT, et al. Decreased bone density in hyperprolactinemic women. New England Journal of Medicine 303: 1511–1514, 1980

    PubMed  CAS  Google Scholar 

  • Konopka P, Raymond JP, Merceron E, Seneze J. Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas. American Journal of Obstetrics and Gynecology 146: 938, 1983

    Google Scholar 

  • Koppleman MCS, Jaffe MJ, Rieth KG, Caruso RC, Loriaux DL. Hyperprolactinemia, amenorrhea and galactorrhea: a retrospective assessment of twenty-five cases. Annals of Internal Medicine 100: 115–121, 1984

    Google Scholar 

  • Lamberts SWJ, Klijn JGM, de Lange S, Singh R, Stefanko SZ, et al. The incidence of complications during pregnancy after treatment of hyperprolactinemia with bromocriptine in patients with radiologically evident pituitary tumors. Fertility and Sterility 31: 614–619, 1979

    PubMed  CAS  Google Scholar 

  • Larsen TA, Newman R, LeWitt P, Calne DB. Severity of Parkinson’s disease and the dosage of bromocriptine. Neurology 34: 795–797, 1984

    PubMed  CAS  Google Scholar 

  • Laws ER, Piepgras DG, Randall RV, Abboud CF. Neurosurgical management of acromegaly: results in 82 patients treated between 1972 and 1977. Journal of Neurosurgery 50: 454–461, 1979

    PubMed  Google Scholar 

  • Lees AJ, Stern GM. Sustained bromocriptine therapy in previously untreated patients with Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry 44: 1020–1023, 1981

    CAS  Google Scholar 

  • Lehtovirta P, Arjomaa P, Ranta T, Laatikainen T, Hirvonen E, et al. Prolactin levels and bromocriptine treatment of short luteal phase. International Journal of Fertility 24: 57–60, 1979

    PubMed  CAS  Google Scholar 

  • Lieberman AN, Goldstein M. Bromocriptine in Parkinson’s disease. Pharmacological Reviews 37: 217–227, 1985

    PubMed  CAS  Google Scholar 

  • Lindholm J, Riishede J, Vestergaard S, Hummer L, Faber O, et al. No effect of bromocriptine in acromegaly: a controlled trial. New England Journal of Medicine 304: 1450–1454, 1981

    PubMed  CAS  Google Scholar 

  • Liuzzi A, Chiodini PG, Botalla L, Cremascoli G, Muller EE, et al. Decreased plasma growth hormone (GH) levels in acromegalics following CB 154(2-Br-alpha-ergocryptine) administration. Journal of Clinical Endocrinology and Metabolism 38: 910–912, 1974

    PubMed  CAS  Google Scholar 

  • Lundin L, Ljunghall S, Wide L, Bostrom H. Bromocriptine therapy in eleven patients with acromegaly. Acta Endocrinologica (Copenhagen) 88 (Suppl. 216): 207–216, 1978

    Google Scholar 

  • Macleod R, Lehmeyer JE. Studies on the mechanism of the dopamine-mediated inhibition of prolactin secretion. Journal of Clinical Endocrinology and Metabolism 94: 1077–1085, 1974

    CAS  Google Scholar 

  • Mansel RE, Preece PE, Hughes LE. Treatment of cyclical breast pain with bromocriptine. Scottish Medical Journal 25: S65–70, 1980

    Google Scholar 

  • March CM, Kletzky DA, Davajan N. Clinical response to CB-154 and the pituitary response to thyrotropin-releasing hormone-gonadotropin-releasing hormone in patients with galactorrhea-amenorrhea. Fertility and Sterility 28: 521–525, 1977

    PubMed  CAS  Google Scholar 

  • March CM, Kletzky OA, Davajan V, Teal J, Weiss M, et al. Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas. American Journal of Obstetrics and Gynecology 139: 835–844, 1981

    PubMed  CAS  Google Scholar 

  • Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson’s disease. Lancet 1: 345–359, 1977

    PubMed  CAS  Google Scholar 

  • Martin TM, Kim M, Malarkey WB. The natural history of idiopathic hyperprolactinemia. Journal of Clinical Endocrinology and Metabolism 60: 855–858, 1985

    PubMed  CAS  Google Scholar 

  • Mims RB, Bethune JE. Acromegaly with normal fasting growth hormone concentrations but abnormal growth hormone regulation. Annals of Internal Medicine 81: 781–784, 1974

    PubMed  CAS  Google Scholar 

  • Molitch ME. Pregnancy and the hyperprolactinemic woman. New England Journal of Medicine 312: 1364–1370, 1985

    PubMed  CAS  Google Scholar 

  • Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter trial. Journal of Clinical Endocrinology and Metabolism 60: 698–705, 1985

    PubMed  CAS  Google Scholar 

  • Montini M, Pagani G, Gianola D, Pagani MD, Salmoiraghi M, et al. Long-lasting suppression of prolactin secretion and rapid shrinkage of prolactinomas after long-acting, injectable form of bromocriptine. Journal of Clinical Endocrinology and Metabolism 63: 266–268, 1986

    PubMed  CAS  Google Scholar 

  • Morgan MY, Jakobovits AW, James IM, Sherklock S. Successful use of bromocriptine in the treatment of chronic hepatic encephalopathy. Gastroenterology 78: 663–670, 1980

    PubMed  CAS  Google Scholar 

  • Moriondo P, Travaglini P, Nissim M, Conti A, Faglia G. Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal. Journal of Clinical Endocrinology and Metabolism 60: 764–772, 1985

    PubMed  CAS  Google Scholar 

  • Muhlenstedt D, Bohnet H, Hanker JP, Schneider HP. Short luteal phase and prolactin. International Journal of Fertility 23: 213–218, 1978

    PubMed  CAS  Google Scholar 

  • Muller EE, Panerai AE, Cocchi D, Mantegazza P. Endocrine profile of ergot alkaloids. Life Sciences 21: 1545–1548, 1977

    PubMed  CAS  Google Scholar 

  • Nabarro JDN. Pituitary prolactinomas. Clinical Endocrinology 17: 129–155, 1982

    PubMed  CAS  Google Scholar 

  • Neill JD, Frawley LS, Plotsky PL, Tindall GT. Dopamine in hypophysial stalk blood of the Rhesus monkey and its role inregulating prolactin secretion. Endocrinology 108: 489–494, 1981

    PubMed  CAS  Google Scholar 

  • Parkes JD, Marsden CD, Donaldson I. Bromocriptine treatment in Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry 39: 184–193, 1976

    CAS  Google Scholar 

  • Perez A, Vela P, Masnick GS, Potter RG. First ovulation after childbirth: effect of breast feeding. American Journal of Obstetrics and Gynecology 114: 1041, 1972

    PubMed  CAS  Google Scholar 

  • Post KD, Biller BJ, Adelman LS, Molitch ME, Wolpert SM, et al. Selective transphenoidal adenomectomy in women with galactorrhea-amenorrhea. Journal of the American Medical Association 242: 158–162, 1979

    PubMed  CAS  Google Scholar 

  • Prescott RWG, Kendall-Taylor P, Hall K, Johnston DG, Crombie A, et al. Hyperprolactinaemia in men — response to bromocriptine therapy. Lancet 1: 245–248, 1982

    PubMed  CAS  Google Scholar 

  • Quabbe HJ. Treatment of acromegaly by transphenoidal operation, 90-yttrium implantation and bromocriptine results in 230 patients. Clinical Endocrinology 16: 107–119, 1982

    PubMed  CAS  Google Scholar 

  • Randall RV, Laws ER, Abboud CF, Ebersold MJ, Kao PC, et al. Transphenoidal microsurgical treatment of prolactin-producing pituitary adenomas: results in 100 patients. Mayo Clinic Proceedings 58: 108–121, 1983

    PubMed  CAS  Google Scholar 

  • Rawe SE, Williamson HO, Levine JH, Phansey SA, Hungerford D, et al. Prolactinomas: surgical therapy, indications and results. Surgical Neurology 14: 161–167, 1980

    PubMed  CAS  Google Scholar 

  • Rolland R. Use of bromocriptine in the inhibition of puerperal lactation. Drugs 17: 326–336, 1979

    PubMed  CAS  Google Scholar 

  • Rolland R, Schellekens LA. Inhibition of puerperal lactation by bromocriptine. Acta Endocrinologica (Copenhagen) 88 (Suppl. 216): 119–130, 1978

    CAS  Google Scholar 

  • Saunders DM, Hunter JC, Haase HR, Wilson GR. Treatment of luteal phase inadequacy with bromocriptine. Obstetrics and Gynecology 53: 287–289, 1979

    PubMed  CAS  Google Scholar 

  • Schran HF, Bhuta SI, Schwartz HJ, Thorner MO. The pharmacokinetics of bromocriptine in man. In Goldstein et al. (Eds) Ergot compounds and brain function: neuroendocrine and neuropsychiatric aspects, pp. 125–139. Advances in Biochemical Psychopharmacology, Vol. 23, Raven Press, New York, 1980

    Google Scholar 

  • Seppala M, Yinen O, Sternthal V, Soiva K, Vara P. Suppression of established lactation with 2-Br-α-ergocryptine methane sulphonate (CB 154). International Journal of Gynaecology and Obstetrics 13: 1–6, 1975

    Google Scholar 

  • Serri O, Rasio E, Beauregard H, Hardy J, Somma M. Recurrence of hyperprolactinemia after selective transphenoidal adenomectomy in women with prolactinoma. New England Journal of Medicine 309: 280–283, 1983

    PubMed  CAS  Google Scholar 

  • Serri O, Somma M, Comtos R, Rasio E, Beauregard H, et al. Acromegaly: biochemical assessment of cure after long term follow-up of transphenoidal selective adenectomy. Journal of Clinical Endocrinology and Metabolism 61: 1185–1189, 1985

    PubMed  CAS  Google Scholar 

  • Shelesnyak MC. Ergotoxin inhibition of deciduoma formation and its reversal by progesterone. American Journal of Physiology 179: 310–304, 1954

    Google Scholar 

  • Shelesnyak MC. Maintenance of gestation in ergotoxine-treated rats by exogenous prolactin. Acta Endocrinologica 27: 99–109, 1958

    PubMed  CAS  Google Scholar 

  • Sherman BM, Korenman SG. Measurement of plasma LH, FSH, estradiol and progesterone in disorders of the human menstrual cycle: the short luteal phase. Journal of Clinical Endocrinology and Metabolism 38: 89–93, 1974

    PubMed  CAS  Google Scholar 

  • Spark RF, Wills CA, O’Reilly G, Ransil BJ, Bergland R. Hyperprolactinaemia in males with and without pituitary macroadenomas. Lancet 2: 129–132, 1982

    PubMed  CAS  Google Scholar 

  • Stonesifer LD, Jordan RM, Kohler PO. Somatomedin C in treated acromegaly: poor correlation with growth hormone and clinical response. Journal of Clinical Endocrinology and Metabolism 53: 931–934, 1981

    PubMed  CAS  Google Scholar 

  • Teychenne PF, Bergsrud D, Racy A. Bromocriptine: low dose therapy in Parkinsonism. Neurology 32: 577–583, 1982

    PubMed  CAS  Google Scholar 

  • Thorner MO, Besser GM. Bromocriptine treatment of hyperprolactinemic hypogonadism. Acta Endocrinologica (Copenhagen) 88 (Suppl. 216): 131–146, 1978

    Google Scholar 

  • Thorner MO, Edwards CR, Charlesworth M. Pregnancy in patients presenting with hyperprolactinaemia. British Medical Journal 21: 771–774, 1979

    Google Scholar 

  • Thorner MO, Perryman RL, Rogol AD. Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine. Journal of Clinical Endocrinology and Metabolism 153: 480–483, 1981

    Google Scholar 

  • Thorner MO, Schran HF, Evans WS, Rogol AD, Morris JL, et al. A broad spectrum of prolactin suppression by bromocriptine in hyperprolactinemic women: a study of serum prolactin and bromocriptine levels after acute and chronic administration of bromocriptine. Journal of Clinical Endocrinology and Metabolism 50: 1026–1033, 1980

    PubMed  CAS  Google Scholar 

  • Tindall GT, Kovacs K, Horvarth E, Thorner MO. Human prolactin producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural and morphometric study. Journal of Clinical Endocrinology and Metabolism 55: 1178–1183, 1982

    PubMed  CAS  Google Scholar 

  • Tucker HStG, Grubb SR, Wigand JP, Taylor A, Lankford HV, et al. Galactorrhea-amenorrhea syndrome: follow up of forty five patients after pituitary tumor removal. Annals of Internal Medicine 94: 302–307, 1981

    PubMed  CAS  Google Scholar 

  • Turkalj I, Braun P, Krupp P. Surveillance of bromocriptine in pregnancy. Journal of the American Medical Association 247: 1589–1591, 1982

    PubMed  CAS  Google Scholar 

  • Turner TH, Cookson JC, Wass JAH, Drury PL, Price PA, et al. Psychotic reactions during treatment of pituitary tumours with dopamine agonists. British Medical Journal 289: 1101–1103, 1984

    PubMed  CAS  Google Scholar 

  • Tyson JE, Hwang P, Guyda H, Friesen H. Studies of prolactin secretion in human pregnancy. American Journal of Obstetrics and Gynecology 113: 14–20, 1972

    PubMed  CAS  Google Scholar 

  • Uribe M, Farca A, Marquez MA, Garcia-Ramos G, Guevara L. Treatment of chronic portal systemic encephalopathy with bromocriptine: a double-blind controlled trial. Gastroenterology 76: 1347–1351, 1979

    PubMed  CAS  Google Scholar 

  • Vance ML, Evans WS, Thorner MO. Bromocriptine. Annals of Internal Medicine 100: 78–91, 1984

    PubMed  CAS  Google Scholar 

  • Veldhuis JD, Klase P, Hammond JM. Divergent effects of prolactin upon steroidogenesis by porcine granulosa cells in vitro; influence of cytodifferentiation. Endocrinology 107: 42–46, 1980

    PubMed  CAS  Google Scholar 

  • Walker S, Hibbard BM, Groom G, Griffiths K, Davis RH. Controlled trial of bromocriptine, Quinestrol and placebo in the suppression of lactation. Lancet 2: 842–844, 1975

    PubMed  CAS  Google Scholar 

  • Wass JA, Clemmons DR, Underwood LE, Barrow I, Besser GM, et al. Changes in circulating somatomedin-C levels in bromocriptine-treated acromegaly. Clinical Endocrinology 17: 369–377, 1982a

    PubMed  CAS  Google Scholar 

  • Wass JA, Thorner MO, Morris DV. Long-term treatment of acromegaly with bromocriptine. British Medical Journal 1: 875–878, 1977

    PubMed  CAS  Google Scholar 

  • Wass JAH, Williams J, Charlesworth M, Kingsley DPE, Halliday AM, et al. Bromocriptine in management of large pituitary tumours. British Medical Journal 284: 1908–1911, 1982b

    PubMed  CAS  Google Scholar 

  • Weinstein D, Ben-David M, Polishuk WZ. Serum prolactin and suppression of lactation. British Journal of Obstetrics and Gynaecology 83: 679–682, 1975

    Google Scholar 

  • Wollesen F, Andersen T, Karle A. Size reduction of extrasellar pituitary tumors during bromocriptine treatment: quantitation of effect on different types of tumors. Annals of Internal Medicine 96: 281–286, 1982

    PubMed  CAS  Google Scholar 

  • Woolf PD. Resumption of prolactin secretion after dopaminergic inhibition: differential effects of dopamine and its agonists. American Journal of Physiology 240: E700–E704, 1981

    PubMed  CAS  Google Scholar 

  • Yeo T, Thorner MO, Jones A, Lowry PJ, Besser GM. The effects of dopamine, bromocriptine, lergotrile, and metoclopramide on prolactin release from continuously perfused columns of isolated rat pituitary cells. Clinical Endocrinology 10: 123–130, 1979

    PubMed  CAS  Google Scholar 

  • Zarate A, Canales ES, Carlos C, Pilonieta CJ. Follow up of patients with prolactinomas after discontinuation of long term therapy with bromocriptine. Acta Endocrinologica (Copenhagen) 104: 139–142, 1983

    CAS  Google Scholar 

  • Zervas NT. Surgical results for pituitary adenomas: results of an international survey. In Black et al. (Eds) Secretory tumors of the pituitary gland, pp. 377–385, Raven Press, New York, 1984

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Garvan Institute of Medical Research, St Vincent’s Hospital, Sydney, Australia

    K. Y. Ho

  2. Department of Internal Medicine, University of Virginia School of Medicine, Charlottesville, Virginia, USA

    M. O. Thorner

Authors
  1. K. Y. Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. O. Thorner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ho, K.Y., Thorner, M.O. Therapeutic Applications of Bromocriptine in Endocrine and Neurological Diseases. Drugs 36, 67–82 (1988). https://doi.org/10.2165/00003495-198836010-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-198836010-00005

Search

Navigation